Suppliers and packagers for VYXEOS

VYXEOS

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401	NDA	Jazz Pharmaceuticals, Inc.	68727-745-01	20 mL in 1 VIAL (68727-745-01)	2017-08-03
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401	NDA	Jazz Pharmaceuticals, Inc.	68727-745-02	40 mL in 1 CARTON (68727-745-02)	2017-08-03

Vyxeos Supplier Analysis

Last updated: February 19, 2026

Vyxeos (daunorubicin and cytarabine) is a liposomal formulation of chemotherapeutic agents used in the treatment of acute myeloid leukemia (AML). Key suppliers for its components and manufacturing are critical for ensuring consistent supply and managing production costs.

What are the Key Active Pharmaceutical Ingredients (APIs) for Vyxeos?

Vyxeos is comprised of two active pharmaceutical ingredients: daunorubicin hydrochloride and cytarabine. These APIs are synthesized or sourced by specialized manufacturers.

• Daunorubicin Hydrochloride: This anthracycline antibiotic is a potent cytotoxic agent. Its production involves complex fermentation and purification processes.
• Cytarabine: Also known as cytosine arabinoside (Ara-C), this antimetabolite is a synthetic nucleoside analog of deoxycytidine. Its synthesis requires advanced organic chemistry capabilities.

Who are the Primary API Manufacturers for Vyxeos?

Identifying the specific, publicly disclosed API manufacturers for a proprietary drug like Vyxeos is challenging due to confidentiality agreements. However, based on general industry knowledge of API production for such complex molecules, potential or known suppliers operate within a specialized segment of the pharmaceutical supply chain.

• Major API Manufacturers with Oncology Capabilities: Companies with established expertise in producing high-potency APIs (HPAPIs) and complex small molecules for oncology are likely involved. These include companies with strong fermentation capabilities for daunorubicin and advanced synthetic chemistry for cytarabine. Examples of companies in this space include (but are not limited to):

  • Lonza: A global contract development and manufacturing organization (CDMO) with extensive API manufacturing capacity, including for oncology drugs.
  • Pfizer CentreOne: The contract manufacturing arm of Pfizer, which offers API development and commercial manufacturing services.
  • Evonik: A specialty chemical company with a significant pharmaceutical division focused on complex APIs and drug delivery systems.
  • Bachem: A leading manufacturer of peptides and oligonucleotides, but also possesses capabilities for complex small molecules and intermediates relevant to chemotherapeutic agents.

• Regional API Hubs: Manufacturing for these complex APIs is often concentrated in regions with established pharmaceutical chemical industries, such as:

  • Europe: Germany, Switzerland, and Italy have a strong presence of specialized API manufacturers.
  • North America: The United States and Canada host several CDMOs with the necessary infrastructure.
  • Asia: India and China are significant players in global API production, though for highly specialized and potent compounds like those in Vyxeos, regulatory compliance and quality standards are paramount.

What are the Critical Excipients and Their Suppliers?

The liposomal formulation of Vyxeos is as critical as its APIs. The lipid components forming the liposome are crucial for drug delivery, stability, and efficacy.

• Key Lipid Components:

  • Cholesterol: A common excipient used to stabilize liposomal membranes.
  • Phospholipids: Such as distearoylphosphatidylcholine (DSPC), which are essential structural components of liposomes.
  • PEGylated Lipids: Such as polyethylene glycol (PEG)-modified lipids, which improve drug circulation time by preventing rapid clearance from the bloodstream.

• Potential Excipient Suppliers: The suppliers of these specialized lipids are typically fine chemical manufacturers and CDMOs with expertise in pharmaceutical-grade lipid synthesis and purification.

  • Croda International: A global specialty chemical company that supplies a range of pharmaceutical excipients, including lipids for drug delivery systems.
  • NOF Corporation: A Japanese chemical company with a dedicated business unit for pharmaceutical lipids, including high-purity phospholipids and PEGylated lipids.
  • Lipoid GmbH: A German company specializing in high-quality phospholipids for pharmaceutical and cosmetic applications.

What are the Manufacturing and Formulation Requirements for Vyxeos?

The manufacture of a liposomal drug product like Vyxeos is a complex, multi-step process requiring specialized facilities and stringent quality control.

• Liposomal Encapsulation: This process involves forming stable liposomes containing both daunorubicin and cytarabine within precise size and composition parameters. It requires:

  • High-Purity Solvents: Pharmaceutical-grade solvents for lipid dissolution and liposome formation.
  • Sterile Processing: Aseptic manufacturing environments to prevent microbial contamination.
  • Particle Size Control: Techniques such as extrusion or sonication to achieve uniform liposome size distribution, critical for drug release kinetics and pharmacokinetic profiles.

• Fill-Finish Operations: Once formulated, the liposomal suspension undergoes sterile filling into vials and lyophilization (if applicable, though Vyxeos is typically a liquid suspension) or direct filling and packaging. This stage necessitates:

  • Specialized Filling Lines: Automated aseptic filling machines designed for sensitive parenteral products.
  • Quality Control Testing: Extensive testing for sterility, potency, purity, particle uniformity, and endotoxins.

Who are the Contract Manufacturing Organizations (CMOs) or CDMOs for Vyxeos?

The development and commercial manufacturing of complex injectable drugs are frequently outsourced to specialized CMOs or CDMOs. While the specific partners for Vyxeos are not publicly disclosed, companies with extensive experience in parenteral drug manufacturing, liposomal technology, and high-potency drug handling are likely involved.

• Key Capabilities of potential CMOs/CDMOs:

  • Aseptic Manufacturing: Extensive experience in sterile processing of injectable drugs.
  • Liposomal Formulation Expertise: Proven track record in developing and manufacturing liposomal drug products.
  • High-Potency API Handling: Facilities and protocols for safely handling cytotoxic APIs.
  • Lyophilization or Liquid Fill/Finish: Capability for the final dosage form production.
  • Regulatory Compliance: Adherence to stringent cGMP standards and successful track record with regulatory agencies (FDA, EMA).

• Leading CDMOs in Parenteral and Oncology Manufacturing:

  • Catalent: A global leader in drug development and manufacturing solutions, with expertise in sterile injectables and complex formulations.
  • Thermo Fisher Scientific (Patheon): Offers comprehensive CDMO services, including sterile fill-finish and development of complex drug products.
  • Recipharm: A European CDMO with broad capabilities in sterile manufacturing, including lyophilized and liquid products.

What are the Regulatory Considerations for Vyxeos Suppliers?

Suppliers for Vyxeos must meet rigorous regulatory standards to ensure the safety, efficacy, and quality of the final drug product.

• Current Good Manufacturing Practices (cGMP): All facilities involved in API synthesis, excipient production, and drug product manufacturing must comply with cGMP regulations as mandated by regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls for the API. Pharmaceutical companies reference these DMFs in their drug applications.
• Quality Agreements: Strong quality agreements between the drug sponsor (Jazz Pharmaceuticals for Vyxeos) and its suppliers are essential. These agreements define quality responsibilities, specifications, change control procedures, and audit rights.
• Supply Chain Security and Traceability: Robust systems for tracking raw materials and finished products throughout the supply chain are critical to prevent counterfeiting and ensure product integrity.

What is the Impact of Supplier Dependence on Vyxeos?

Dependence on a limited number of suppliers for critical APIs or specialized excipients can pose significant risks to the consistent supply of Vyxeos.

• Supply Chain Vulnerabilities: Disruptions at a single supplier facility due to natural disasters, geopolitical instability, regulatory issues, or production problems can lead to drug shortages.
• Cost Volatility: The pricing of specialized APIs and excipients can fluctuate based on raw material availability, manufacturing complexity, and supplier market power, impacting the overall cost of goods for Vyxeos.
• Quality Control Risks: Maintaining consistent quality across different suppliers and manufacturing sites requires robust oversight. Any deviation in quality from a supplier can impact the safety and efficacy of the final product.
• Intellectual Property and Confidentiality: For proprietary formulations, stringent measures are needed to protect intellectual property and maintain the confidentiality of manufacturing processes with external suppliers.

Key Takeaways

• Vyxeos's critical components include the APIs daunorubicin hydrochloride and cytarabine, along with specialized lipid excipients for its liposomal formulation.
• Manufacturing of these components is likely undertaken by specialized API manufacturers with expertise in oncology and complex synthesis, and by fine chemical companies producing pharmaceutical-grade lipids.
• Complex injectable drug products like Vyxeos are often manufactured by Contract Development and Manufacturing Organizations (CDMOs) possessing aseptic processing, liposomal formulation, and high-potency handling capabilities.
• Suppliers must adhere to stringent cGMP regulations, and robust quality agreements are crucial for ensuring product quality and supply chain integrity.
• Dependence on a limited supplier base for critical inputs creates vulnerabilities in supply chain stability and can lead to cost volatility.

Frequently Asked Questions

1. How is the liposomal formulation of Vyxeos achieved?

The liposomal formulation of Vyxeos is achieved through a complex process that involves encapsulating daunorubicin and cytarabine within lipid vesicles. This process typically utilizes specialized equipment and high-purity lipid excipients like cholesterol, phospholipids (e.g., DSPC), and PEGylated lipids to create stable liposomes of controlled size and composition, ensuring the intended drug release and pharmacokinetic profile.

2. What are the primary risks associated with the Vyxeos supply chain?

The primary risks associated with the Vyxeos supply chain include dependence on a limited number of specialized suppliers for APIs and lipid excipients, potential manufacturing disruptions at supplier sites, cost volatility of raw materials and specialized components, and maintaining consistent quality across all manufacturing stages and suppliers.

3. How do pharmaceutical companies ensure the quality of APIs supplied for drugs like Vyxeos?

Pharmaceutical companies ensure API quality through rigorous supplier qualification processes, including audits of manufacturing facilities and quality systems. They establish detailed quality agreements that define specifications, testing methods, change control procedures, and incident reporting. Batch-to-batch testing of incoming APIs and ongoing monitoring of supplier performance are also critical measures.

4. Are there alternative suppliers for the key lipids used in Vyxeos?

While specific lipid compositions are proprietary, the market for pharmaceutical-grade lipids is served by several global manufacturers with specialized capabilities. Companies like Croda, NOF Corporation, and Lipoid GmbH are established providers of high-purity phospholipids and PEGylated lipids. The availability of alternatives would depend on the exact proprietary lipid structures and their patent status.

5. What is the role of regulatory agencies in overseeing Vyxeos suppliers?

Regulatory agencies, such as the FDA and EMA, oversee Vyxeos suppliers by enforcing Current Good Manufacturing Practices (cGMP). They review manufacturing processes and quality controls through Drug Master Files (DMFs) submitted by API manufacturers and through inspections of manufacturing facilities for both API production and drug product manufacturing. Approval of these suppliers is integral to the drug's marketing authorization.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Drug Master Files; Guidance for Industry and FDA Staff. Retrieved from [relevant FDA website, specific document or page would be cited here if available] [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [relevant EMA website, specific document or page would be cited here if available] [3] Jazz Pharmaceuticals. (2017). Vyxeos (daunorubicin and cytarabine) liposomal: Prescribing Information. Retrieved from [specific product label or prescribing information source]